These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37435666)

  • 1. Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
    M Hidjo MM; Chikwambi Z; Ngwende G; Matenga JA; Masimirembwa C
    Pharmacogenomics; 2023 Jul; 24(10):529-538. PubMed ID: 37435666
    [No Abstract]   [Full Text] [Related]  

  • 2. Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
    Ndadza A; Muyambo S; Mntla P; Wonkam A; Chimusa E; Kengne AP; Ntsekhe M; Dandara C
    J Thromb Haemost; 2021 Dec; 19(12):2957-2973. PubMed ID: 34382722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
    Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
    Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.
    Vear SI; Ayers GD; Van Driest SL; Sidonio RF; Stein CM; Ho RH
    Br J Haematol; 2014 Jun; 165(6):832-5. PubMed ID: 24601977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
    Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
    Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.
    Flockhart DA; O'Kane D; Williams MS; Watson MS; Flockhart DA; Gage B; Gandolfi R; King R; Lyon E; Nussbaum R; O'Kane D; Schulman K; Veenstra D; Williams MS; Watson MS;
    Genet Med; 2008 Feb; 10(2):139-50. PubMed ID: 18281922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
    Takahashi H; Wilkinson GR; Nutescu EA; Morita T; Ritchie MD; Scordo MG; Pengo V; Barban M; Padrini R; Ieiri I; Otsubo K; Kashima T; Kimura S; Kijima S; Echizen H
    Pharmacogenet Genomics; 2006 Feb; 16(2):101-10. PubMed ID: 16424822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
    Sridharan K; Sivaramakrishnan G
    J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.